Top News
Home >> Marketplace Archives >> CMS extends coverage of Oncomine Dx test, 5/18

CMS extends coverage of Oncomine Dx test, 5/18

Print Friendly, PDF & Email

 

May 2018—Thermo Fisher Scientific announced its Oncomine Dx Target Test has been approved for coverage by the Centers for Medicare and Medicaid Services as part of the agency’s national coverage determination for next-generation sequencing in vitro diagnostic tests. Combined with positive reimbursement decisions from commercial health insurers, the test is now available to more than 160 million people in the U.S.

The Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.

Thermo Fisher Scientific, 866-356-0354

x

Check Also

Thermo Fisher expands Oncomine portfolio, 4/18

April 2018—Thermo Fisher Scientific has expanded its Oncomine portfolio with two assays for liquid biopsy and immuno-oncology for clinical research. The company also announced its next-generation Ion AmpliSeq HD technology. The Ion Torrent Oncomine Pan-Cancer Cell-Free Assay enables reproducible detection and analysis of tumor DNA and RNA across all major classes of somatic mutations (SNVs, indels, CNVs, and fusions) from a single vial of blood, with as little as 1 ng of nucleic acid input, within two days.

X